Ac Immune Sa · NASDAQ:ACIU
Ac Immune Sa — Shareholder Meeting (June 2025)
47 slides from Ac Immune Sa's shareholder meeting presentation, Jun 20, 2025
Slide 1: Investor Update – Annual General Meeting June 19, 2025
NASDAQ: ACIU | AGM Presentation, June 2025 © 2025 AC Immune. Not to be used or reproduced without permission Investor Update NASDAQ: ACIU | Annual General Meeting – June 19, 2025 PIONEERING PRECISION MEDICINE TARGETED THERAPEUTICS FOR NEURODEGENERATIVE DISEASES
Slide 2: Disclaimer
Disclaimer 2 NASDAQ: ACIU | AGM Presentation, June 2025 © 2025 AC Immune. Not to be used or reproduced without permission This presentation contains statements that constitute “forward - looking statements” within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Secu
Slide 3: Agenda
Agenda 3 NASDAQ: ACIU | AGM Presentation, June 2025 © 2025 AC Immune. Not to be used or reproduced without permission AC Immune’s approach to neurodegenerative diseases 1. Achievements 2024 2. Business strategy and pipeline update 3. Clinical - stage active immunotherapy programs 4. Programs targeti
Slide 4: AC Immune's approach to neurodegenerative diseases
1. AC Immune’s approach to neurodegenerative diseases
Slide 5: AC Immune today – an overview
AC Immune today – an overview Pioneering next generation Precision Medicine for neurodegenerative diseases ■ Based in Lausanne, Switzerland ■ ~170 employees ■ Listed September 2016 (NASDAQ: ACIU) ■ 100.6 million shares outstanding 1 ■ Cash resources of CHF 145.7 million 2 Diverse and balanced pipeli
Slide 6: Neurodegenerative diseases: prevention as the best approach
Neurodegenerative diseases mAb 3 treatment 315 69 32 Active immunotherapy for treatment and prevention Diagnostics enable earlier intervention Preclinical AD Prodromal AD AD Dementia A beta T au a - syn 5 TDP - 43 6 Neuro - i n fl ammat io n ALS 7 L A T E 8 Parkinson’s Disease / Lewy body dementia A
Slide 7: Achievements 2024
2. Achievements 2024
Slide 8: AC Immune 2024 highlights
AC Immune 2024 highlights The foundation for early detection and treatment 8 Cash runway permits achievement of key milestones & execution of value - generating innovation Strong financial position (1) Phase 1b/2; (2) Phase 2b; (3) Phase 2; (4) Alpha - synuclein; (5) (NOD) - like receptor protein 3;
Slide 9: Business strategy and pipeline update
3. Business strategy and pipeline update
Slide 10: AC Immune's four core value-driving pillars
AC Immune’s four core value - driving pillars Combining biomarker - based clinical development, validated targets and strong collaborations The only active immunotherapy in a prevention study for pre - symptomatic Alzheimer’s disease ACI - 35.030 anti - pTau Biomarker - driven development targeting
Slide 11: Broad and robust pipeline in neurodegenerative diseases
Indication Candidate Partner Mo d al i ty Discovery Prec linical Phase 1 Phase 2 Phase 3 Parkinson’s disease A C I - 7104 . 05 6 anti - a - syn 1 active immunotherapy Morphomer ® a - syn anti - a - syn small molecule Neuro - inflammation ACI - 19764 anti - NLRP3 2 small molecule inhibitor Anti - NLR
Slide 12: Precision medicine approach enabled by the Morphomer platform
Precision medicine approach enabled by the Morphomer ® platform Developing a suite of tracers against emerging targets in neurodegenerative diseases (1) alpha - synuclein; (2) Positron emission tomography; (3) Multiple system atrophy; (4) Amyotrophic lateral sclerosis; (5) TAR DNA - binding protein
Slide 13: Technology platforms driving value-creating pharma deals
Technology platforms driving value - creating pharma deals Strategy: optimize value to risk ratio and retain significant upside ■ Over CHF 400 million in upfront payments from deals; further >CHF 4.3 billion possible ■ Considerable additional potential value in our unpartnered clinical and preclinic
Slide 14: Clinical-stage active immunotherapy programs
4. Clinical - stage active immunotherapy programs
Slide 15: Active immunotherapies driving Precision Prevention
(1) Alzheimer’s disease; (2) Down syndrome - related Alzheimer’s disease; (3) alpha - synuclein; (4) Parkinson’s disease NASDAQ: ACIU | AGM Presentation, June 2025 © 2025 AC Immune. Not to be used or reproduced without permission 15 Active immunotherapies driving Precision Prevention Three clinical
Slide 16: Active immunotherapy advantages over passive immunotherapy
targeting neurodegenerative diseases Long - lasting specific immunity for pathological target, consistent, boostable Limited annual dosing (once or twice) after priming year No observed ARIA - E 1 to date (safety profile well suited to long - term use) Ease of administration and simple logistics for
Slide 17: Active immunotherapy: a new class of treatment
NASDAQ: ACIU | AGM Presentation, June 2025 © 2025 AC Immune. Not to be used or reproduced without permission 17 Active immunotherapy: a new class of treatment for neurodegenerative disease Potential for profound social and economic impact Treatment Maintenance Prevention for global treatment and pre
Slide 18: Programs targeting a-syn and NLRP3 inflammasome
5. Programs targeting a - syn and NLRP3 inflammasome
Slide 19: AC Immune's four core value-driving pillars
AC Immune’s four core value - driving pillars Combining biomarker - based clinical development, validated targets and strong collaborations The only active immunotherapy in a prevention study for pre - symptomatic Alzheimer’s disease 19 NASDAQ: ACIU | AGM Presentation, June 2025 © 2025 AC Immune. No
Slide 20: Pioneering a-syn modalities to address Parkinson's disease
▪ Active immunotherapy targeting pathological oligomeric a - syn to prevent spreading and neurodegeneration ▪ In Phase 2 trial in early PD 2 with safety and immunogenicity data reported in H2 2024 ▪ Morphomer® diagnostic PET 4 tracers for pathological a - syn aggregates to detect and differentiate a
Slide 21: AC Immune's four core value-driving pillars
AC Immune’s four core value - driving pillars Combining biomarker - based clinical development, validated targets and strong collaborations The only active immunotherapy in a prevention study for pre - symptomatic Alzheimer’s disease 21 NASDAQ: ACIU | AGM Presentation, June 2025 © 2025 AC Immune. No
Slide 22: NLRP3 Inflammasome is a promising therapeutic target
NLRP3 1 Inflammasome is a promising therapeutic target Key disease driver in multiple CNS and other diseases ■ Mechanism of action can be applied across a broad range of neuroinflammatory and other diseases ■ Pharmacological inhibition of NLRP3 lowers aberrant cytokine release and reduces disease pa
Slide 23: Key milestones 2025
6. Key milestones 2025
Slide 24: Key milestones 2025
NASDAQ: ACIU | AGM Presentation, June 2025 © 2025 AC Immune. Not to be used or reproduced without permission H2’25 H1’25 Active immunotherapies ABATE Phase 2 trial 12 - month treatment completed in AD 1 Dec. 2025 Abeta ACI - 24.060 (Takeda) Phase 2 VacSYn trial in PD 3 : Part 1 interim results, phar
Slide 25: Financial figures
7. Financial figures
Slide 26: 2024 Financial Overview
2024 Financial Overview Key financial data (IFRS) 26 NASDAQ: ACIU | AGM Presentation, June 2025 © 2025 AC Immune. Not to be used or reproduced without permission Ch a ng e 2023 2024 For the year ended December 31, (in CHF million) (except per share data) 12 .5 14.8 27 .3 Revenues (8. 0) (54. 6) ( 62
Slide 27: AC Immune strong Balance Sheet
AC Immune strong Balance Sheet Operations well - funded into 2027 Astute investment strategy focused on major value drivers and near - term catalysts Strong Balance Sheet 2 Cash runway into Q1 2027 2025 annual cash burn guidance CHF 75m – 85m Cash of CHF 145.7 million 1 (1) As of March 31, 2025; (2)
Slide 28: Strong track record in deals with leading pharma companies
AC Immune strong track record in deals 1 with leading pharma companies Strategy: optimize value to risk ratio and retain significant upside (1) Disclosure limited due to confidentiality agreements with collaboration partners; (2) In millions; (3) Total payments received from partner until conclusion
Slide 29: Technology platforms driving validating pharma deals
AC Immune technology platforms driving validating pharma deals Strategy: optimize value to risk ratio and retain significant upside ■ An integrated approach to Central Nervous System (CNS) - specific therapies Platform Program Partner A C I - 24 .0 6 0 A C I - 35 .0 3 0 Mor Tau Tau PET SupraAntigen
Slide 30: Summary and Strategic outlook
8. Summary and Strategic outlook
Slide 31: Creating the future of Precision Medicine in neurodegeneration
Creating the future of Precision Medicine in neurodegeneration The foundation for early detection and treatment Cash runway enables achievement of key milestones & execution of value - generating innovation Advance clinical - stage active immunotherapies Strong financial position (1) Phase 1b/2; (2)
Slide 32: Shifting the treatment paradigm towards precision medicine and prevention
Shifting the treatment paradigm for neurodegenerative disease towards precision medicine and disease prevention 32 NASDAQ: ACIU | AGM Presentation, June 2025 © 2025 AC Immune. Not to be used or reproduced without permission AC Immune: Pioneering science and precision medicine
Slide 33: Agenda items and proposals of the Board of Directors
9. Agenda items and proposals of the Board of Directors
Slide 34: Approval of 2024 IFRS and Statutory Financial Statements
Agenda item 1 34 NASDAQ: ACIU | AGM Presentation, June 2025 © 2025 AC Immune. Not to be used or reproduced without permission 2024 IFRS Consolidated Financial Statements, 2024 Statutory Financial Statements and 2024 Compensation Report 1.1 Approval of 2024 IFRS Consolidated Financial Statements and
Slide 35: Advisory vote on the 2024 Compensation Report
Agenda item 1 35 NASDAQ: ACIU | AGM Presentation, June 2025 © 2025 AC Immune. Not to be used or reproduced without permission 2024 IFRS Consolidated Financial Statements, 2024 Statutory Financial Statements and 2024 Compensation Report 1.2 Advisory vote on the 2024 Compensation Report ■ The Board pr
Slide 36: Appropriation of Losses
Agenda item 2 Appropriation of Losses 36 NASDAQ: ACIU | AGM Presentation, June 2025 © 2025 AC Immune. Not to be used or reproduced without permission ■ The Board proposes the following appropriation of losses: In CHF K (310,998) Accumulated profit (loss) at Jan 1, 2024 (45,848) Net profit (loss) for
Slide 37: Discharge of the Board and Executive Committee
Agenda item 3 Discharge of the Members of the Board of Directors and the Executive Committee 37 NASDAQ: ACIU | AGM Presentation, June 2025 © 2025 AC Immune. Not to be used or reproduced without permission ■ The Board proposes that all Members of the Board and of the Executive Committee (EC) be disch
Slide 38: Board compensation vote
Agenda item 4 Compensation for the Members of the Board of Directors and the Executive Committee 38 NASDAQ: ACIU | AGM Presentation, June 2025 © 2025 AC Immune. Not to be used or reproduced without permission 4.1 Binding vote on maximum aggregate compensation for Members of the Board from the AGM 20
Slide 39: Executive Committee compensation vote
Agenda item 4 Compensation for the Members of the Board of Directors and the Executive Committee 39 NASDAQ: ACIU | AGM Presentation, June 2025 © 2025 AC Immune. Not to be used or reproduced without permission 4.2 Binding vote on maximum aggregate compensation for Members of the Executive Committee f
Slide 40: Re-election of Members of the Board of Directors
Agenda item 5 Re - elections and Elections 40 NASDAQ: ACIU | AGM Presentation, June 2025 © 2025 AC Immune. Not to be used or reproduced without permission 5.1 Re - election of Members of the Board of Directors ■ The Board proposes that each of the following persons be re - elected as Member of the B
Slide 41: Election of Board Members and Chair
Agenda item 5 Re - elections and Elections 41 NASDAQ: ACIU | AGM Presentation, June 2025 © 2025 AC Immune. Not to be used or reproduced without permission 5.2 Election of Members and the Chair of the Board of Directors ■ The Board proposes that each of the following persons be elected for a term of
Slide 42: Re-election of Compensation Committee Members
Agenda item 5 Re - elections and Elections 42 NASDAQ: ACIU | AGM Presentation, June 2025 © 2025 AC Immune. Not to be used or reproduced without permission 5.3 Re - election of Members of the Compensation, Nomination and Corporate Governance Committee ■ The Board proposes that: ■ Monika Bütler, and ■
Slide 43: Election of Compensation Committee Member
Agenda item 5 Re - elections and Elections 43 NASDAQ: ACIU | AGM Presentation, June 2025 © 2025 AC Immune. Not to be used or reproduced without permission 5.4 Election of Member of the Compensation, Nomination and Corporate Governance Committee ■ The Board proposes that Martin Zügel be elected as Me
Slide 44: Re-election of the Statutory Auditors
Agenda item 5 Re - elections and Elections 44 NASDAQ: ACIU | AGM Presentation, June 2025 © 2025 AC Immune. Not to be used or reproduced without permission 5.5 Re - election of the Statutory Auditors ■ The Board proposes that PricewaterhouseCoopers SA, in Pully, Switzerland, be re - elected as Statut
Slide 45: Re-election of the Independent Proxy
Agenda item 5 Re - elections and Elections 45 NASDAQ: ACIU | AGM Presentation, June 2025 © 2025 AC Immune. Not to be used or reproduced without permission 5.6 Re - election of the Independent Proxy ■ The Board proposes that Reymond & Associés Attorneys in Lausanne, Switzerland be re - elected as Ind
Slide 46: Changes in the Articles of Association
Agenda item 6 Changes in the Articles of Association 46 NASDAQ: ACIU | AGM Presentation, June 2025 © 2025 AC Immune. Not to be used or reproduced without permission ■ The Board of Directors has withdrawn its proposals for agenda items 6.1 and 6.2
Slide 47: We thank you for your attendance and your continued support
We thank you for your attendance and your continued support. 47 NASDAQ: ACIU | AGM Presentation, June 2025 © 2025 AC Immune. Not to be used or reproduced without permission